Drug profile

The FDA adverse-event record for Dappv

24 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Dappv. Species, reactions, and outcomes follow.

#1618 of 2,679
by report volume (all drugs)
24
adverse-event reports
12.5%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Dappv ranks #1609 of 2679 by total reports (24). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1609
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Dappv has 24 reports now versus 19 in that prior snapshot: 5 more (26.3%).

Report change
+5
Death-coded reports
+1
Death-coded share
+2.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Dappv changes

Signature read: report volume at 24 is the most distinctive stamp on Dappv's FDA AER row.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
24
Total Reports
3
Deaths Reported
12.5%
Death-coded share of reports

Active Ingredients

Dappv

Administration Routes

SubcutaneousUnknown

Species Affected

Dog 24

Most Affected Breeds

Crossbred Canine/dog 7
Retriever - Labrador 4
Chihuahua 3
Retriever - Golden 2
Dachshund (unspecified) 1
Spaniel (unspecified) 1
Bulldog - American 1
Shepherd Dog - Australian 1
Dogo Argentino 1
Siberian Husky 1

Most Reported Reactions

Vomiting 6
Emesis (multiple) 4
Death by euthanasia 3
Weight loss 3
Restlessness 3
Hypersensitivity reaction 3
Panting 3
Seizure NOS 2
Increased percentage reticulocytes 2
Nystagmus 2
Lethargy (see also Central nervous system depression in Neurological) 2
Unwell 2

Outcome Breakdown

Ongoing
10 (41.7%)
Recovered/Normal
8 (33.3%)
Euthanized
3 (12.5%)
Outcome Unknown
3 (12.5%)

Dappv Adverse Event Insights

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Dappv (#1618 of 2,679 by report volume); death-coded 12.5%. PlainBreed drug row · report volume stamp 24 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →